Systemic complement protein levels as biomarkers of chemoradiotherapy response in anal squamous cell carcinoma
These findings suggest that dysregulation of the complement system, particularly involving the alternative pathway, may be more prevalent in patients with a poor treatment response. Intact C2 and Factor D may represent potential markers of treatment failure.
Authors
- D. Majorová
- Muhammad Ismail (ORCID: https://orcid.org/0000-0002-7019-2146)
- Alexander Hasson (ORCID: https://orcid.org/0000-0003-0815-9203)
- Adel Samson (ORCID: https://orcid.org/0000-0002-3081-7850)
- Brian David Nicholson (ORCID: https://orcid.org/0000-0003-0661-7362)
- D. Sebag-Montefiore
- R. Muirhead
- Robert Samuel (ORCID: https://orcid.org/0000-0001-9625-2111)
- Edward O’Neill (ORCID: https://orcid.org/0000-0002-7987-8160)
- C. Jacobs
- David MacLean (ORCID: https://orcid.org/0000-0003-4932-2839)
- Monica M. Olcina (ORCID: https://orcid.org/0000-0001-9580-2169)
- Mark Saunders
- David Halliday
- Eleanor J. Cheadle
Institutions
- University of Leeds (GB)
- Churchill Hospital (GB)
- St James's University Hospital (GB)
- University of Manchester (GB)
- University of Oxford (GB)
- CRUK/MRC Oxford Institute for Radiation Oncology (GB)
- Cancer Research UK Manchester Institute (GB)
- The Christie NHS Foundation Trust (GB)
- Oxford University Hospitals NHS Trust (GB)
Publication Details
- Journal
- Radiotherapy and Oncology
- Published
- 2025-12-07
- DOI
- https://doi.org/10.1016/j.radonc.2025.111324
- Primary Topic
- Colorectal and Anal Carcinomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wellcome Trust
- Cancer Research UK
- National Institute for Health and Care Research
- British Heart Foundation
- Diabetes UK
- University of Oxford
- Manchester Biomedical Research Centre
- HORIZON EUROPE Framework Programme
- NIHR Oxford Biomedical Research Centre